All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-03-01T11:27:33.000Z

A phase I/II trial of pirtobrutinib in patients with R/R Waldenstrom’s macroglobulinemia (BRUIN trial)

By Bryan Mc Swiney
Mar 1, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in Waldenstrom’s macroglobulinemia.

Bookmark this article

The Lymphoma Hub is happy to present a visual abstract representing key data from the phase I/II BRUIN trial (NCT03740529) evaluating the safety and efficacy of pirtobrutinib, a reversible (non-covalent) Bruton’s tyrosine kinase inhibitor, in heavily pretreated patients with relapsed/refractory Waldenstrom’s macroglobulinemia, as presented at the 64th American Society of Hematology Annual Meeting and Exposition. In June 2021, the Lymphoma Hub reported preliminary results of the trial.


 

Visual Abstract

To download this visual abstract, click below.

Download here

More about...
ASH 2022BRUINIndolent B-cell lymphomasPirtobrutinibWaldenström’s macroglobulinemia

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Pirtobrutinib granted FDA approval for the treatment of R/R MCL

On January 27, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for...

Jan 30, 2023
Add bookmark

Pirtobrutinib granted FDA approval for the treatment of R/R MCL

On January 27, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to pirtobrutinib, a...

Jan 30, 2023
Add bookmark

Genomic pathways and treatment strategies for patients with Waldenstrom’s macroglobulinemia

Despite the rarity of WM there has been vast progression of WM treatments in both frontline and relapsed/refractory (R/R) settings. Advancements in...

Oct 13, 2022
Add bookmark

Genomic pathways and treatment strategies for patients with Waldenstrom’s macroglobulinemia

Despite the rarity of WM there has been vast progression of WM treatments in both frontline and...

Oct 13, 2022

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox